Table 2.
Subgroup analysis of CDI occurrence under OVP versus no intervention in the overall population.
| Variable | Included Studies, n | Sample Size, n | OR (95% CI) | I2 | Test for Subgroup Difference, p Value |
|---|---|---|---|---|---|
| Study place | 0.51 | ||||
| US | 9 | 2095 | 0.15 (0.06–0.36) | 59% | |
| Not US | 2 | 845 | 0.31 (0.04–2.26) | 0% | |
| Study design | 0.99 | ||||
| Retrospective | 10 | 2840 | 0.19 (0.09–0.44) | 59.4% | |
| Prospective | 1 | 100 | 0.07 (0.00–1.24) | - | |
| Study population | 0.30 | ||||
| Adult hospitalized | 6 | 1999 | 0.27 (0.10–0.78) | 64.1% | |
| SOT | 2 | 672 | 0.16 (0.02–1.21) | 0% | |
| Hematological | 2 | 195 | 0.03 (0.00–0.23) | 0% | |
| Pediatric | 1 | 74 | 0.10 (0.01–0.85) | - | |
| OVP dose * | 0.11 | ||||
| 125 mg od | 2 | 344 | 0.06 (0.01–0.48) | 0% | |
| 125 bid | 5 | 951 | 0.11 (0.04–0.32) | 0% | |
| Other (variable/mixed dosages) | 4 | 1645 | 0.43 (0.15–1.23) | 78.5% | |
| Timing of follow-up | <0.01 | ||||
| 28/30-day | 2 | 239 | 0.12 (0.03–0.39) | 0% | |
| 90-day | 3 | 1461 | 0.82 (0.61–1.11) | 0% | |
| In-hospital | 3 | 1025 | 0.03 (0.00–0.22) | 0% | |
| Other | 3 | 207 | 0.12 (0.04–0.36) | 0% | |
| Mean duration of OVP | 0.01 | ||||
| (Compared with SAT) | |||||
| Longer | 7 | 1244 | 0.08 (0.03–0.18) | 0% | |
| Shorter | 4 | 1696 | 0.44 (0.16–1.23) | 40% |
* The analysis was not run under a GLMM as this model could not be fit, but rather through MH method without continuity correction. Abbreviations: bis: bis in die; CDI: Clostridioides difficile infection; MH, Mantel–Haenszel; od, once a day; OR, odds ratio; OVP, oral vancomycin prophylaxis; SAT, systemic antibiotic therapy; SOT, solid organ transplantation; US, United States; 95%-CI, confidence intervals at 95%.